The clinical impact of identifying metabolic syndrome in patients with diabetes: A cross-sectional study

Diabetes and Vascular Disease Research

Volumn 6, Issue 1, 2009, Pages 21-24

  Bulugahapitiya, Uditha ^a,b   Siyambalapitiya, Sajith ^a,b   Sithole, Jabulani ^c   Fernando, Devaka J ^a,b,d   Idris, Iskandar ^a,b  

^a SHERWOOD FOREST HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

Cardiovascular disease; Diabetes; Metabolic syndrome; Primary prevention; Statin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL DECISION MAKING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DATA ANALYSIS; DIABETIC PATIENT; DRUG USE; FEMALE; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METABOLIC SYNDROME X; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY PREVENTION; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIABETES COMPLICATIONS; DIABETIC ANGIOPATHIES; FEMALE; GREAT BRITAIN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; SENSITIVITY AND SPECIFICITY;

EID: 59149093320     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2009.004     Document Type: Article

References (25)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1596-607.
2. Sattar N, Gaw A, Scherbakova O et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-19.
3. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356-9.
4. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24:683-9.
5. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004; 173:309-14.
6. Executive summary of the third report of the National Cholesterol Education Programme (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
7. JBS-2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; 91(suppl v):v1-v52.
8. The National Institute for Health and Clinical Excellence (NICE). Statins for the prevention of cardiovascular events. Technology Appraisal 94. January 2006 www.nice.org.uk/page.aspx?o=TA094guidance
9. Deedwania P, Barter P, Carmena R et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006;368:919-28.
10. Kahn R, Buse, Ferrannini E, Stern M. The metabolic syndrome: Time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes 2005;28:2289-304.
11. Kahn R. Metabolic syndrome - what is the clinical usefulness? Lancet 2008;371:1892-3.
12. Sattar N, McConnachie A, Shaper AG et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 2008;371:1927-35.
13. Roland MO. Linking physicians' pay to the quality of care: a major experiment in the United Kingdom. N Engl J Med 2004; 351:1448-54.
14. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16:393-401.
15. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006;23:469-80.
16. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995;311:158-61.
17. Robins SJ. Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy? Current Opin Lipidol 2003;14:575-83.
18. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006;29:1478-85.
19. Stern MP, Williams K, Gonzalez-Villapando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004;27:2676-81.
20. Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006;332:878-82.
21. Guzder RN, Gatling W, Mullee MA, Byrne CD. Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia 2006;49:49-55.
22. Scheen AJ. Does the metabolic syndrome help select patients requiring high statin dose? Lancet 2006;368:893-4.
23. Gami AS, Witt BJ, Howard DE et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49:403-14.
24. Song SH, Brown PM. Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabet Med 2004; 21:238-45.
25. Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study. Diabet Med 2005; 22:554-62.